BriaCell Therapeutics (OTCMKTS:BCTXF) Stock Price Down 2.9%

Shares of BriaCell Therapeutics Corp. (OTCMKTS:BCTXFGet Free Report) were down 2.9% on Thursday . The company traded as low as $0.68 and last traded at $0.70. Approximately 59,940 shares were traded during mid-day trading, an increase of 3,124% from the average daily volume of 1,859 shares. The stock had previously closed at $0.72.

BriaCell Therapeutics Price Performance

The firm has a market capitalization of $562,788.00, a price-to-earnings ratio of -0.18 and a beta of 1.09. The business has a fifty day moving average price of $0.79 and a two-hundred day moving average price of $1.74.

BriaCell Therapeutics Company Profile

(Get Free Report)

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.

Featured Articles

Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.